Lexitas and Ocusun Dose First Patient in Cataract Trial
DURHAM, N.C. & GUANGZHOU, China, July 14, 2026 Lexitas Pharma Services and Ocusun have announced the enrollment of the...
phase III trial
Advertisement
Apnimed Targets First Oral Sleep Apnea Therapy with FDA NDA
CAMBRIDGE, Mass., July 14, 2026 Apnimed, Inc. has achieved a significant regulatory milestone after the U.S. Food and Drug...
Lynk Pharmaceuticals Completes Phase III AS Trial Enrollment
HANGZHOU, China, SHANGHAI & BOSTON — July 14, 2026 Lynk Pharmaceuticals Co., Ltd. has announced the successful completion of...
Hansoh Pharma Reports Positive Phase III Ris-Rez SCLC Results
SHANGHAI, China, July 10, 2026 Hansoh Pharmaceutical Group Co., Ltd. has announced that its Phase III ARTEMIS-008 clinical trial...
AstraZeneca Reports Wainua Phase III ATTR-CM Trial Results
CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...
Advertisements
Octapharma USA Expands FDA Approval for wilate® in Children
PARAMUS, N.J. | July 8, 2026 Octapharma USA has announced that the U.S. Food and Drug Administration (FDA) has...
Ipsen Reports Positive Phase III Dysport Migraine Results
PARIS, France, July 9, 2026 Ipsen has announced positive topline Phase III results from its BEOND clinical development program,...
Sino Biopharm Secures $2.1B TQC3721 AstraZeneca Agreement
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
Insilico Begins Phase III Trial of AI-Designed IPF Therapy
CAMBRIDGE, Mass., July 7, 2026 Insilico Medicine has announced the initiation of its Phase III clinical trial evaluating Rentosertib,...
Roche’s Divarasib Beats Approved KRAS Therapies in Phase III Trial
Basel, Switzerland, July 2, 2026 Roche has announced positive top-line results from its pivotal Phase III Krascendo 1 clinical...
Advertisement
